olomoucine has been researched along with Nerve Degeneration in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hyun, HW; Kim, JE; Min, SJ | 1 |
| Bu, B; Chakrabarty, P; Li, J; Vincent, I; Zhang, M | 1 |
| Milton, NG | 1 |
1 review(s) available for olomoucine and Nerve Degeneration
| Article | Year |
|---|---|
Phosphorylated amyloid-beta: the toxic intermediate in alzheimer's disease neurodegeneration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cyclin-Dependent Kinases; Enzyme Inhibitors; Humans; Kinetin; Nerve Degeneration; Phosphoproteins; Phosphorylation; Purines | 2005 |
2 other study(ies) available for olomoucine and Nerve Degeneration
| Article | Year |
|---|---|
CDK5 inhibitors prevent astroglial apoptosis and reactive astrogliosis by regulating PKA and DRP1 phosphorylations in the rat hippocampus.
Topics: Animals; Apoptosis; Astrocytes; CA1 Region, Hippocampal; Cyclic AMP-Dependent Protein Kinases; Cyclin-Dependent Kinase 5; Dentate Gyrus; Dynamins; Gliosis; Kinetin; Male; Nerve Degeneration; Phosphorylation; Protein Kinase Inhibitors; Purines; Rats; Roscovitine; Status Epilepticus | 2017 |
Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice.
Topics: Animals; Apoptosis; Cyclin-Dependent Kinases; Cytoskeleton; Disease Models, Animal; Enzyme Inhibitors; Female; Humans; Intracellular Signaling Peptides and Proteins; Kinetin; Male; Mice; Mice, Inbred BALB C; Mice, Neurologic Mutants; Motor Activity; Nerve Degeneration; Neurons; Niemann-Pick C1 Protein; Niemann-Pick Diseases; Phosphorylation; Proteins; Purines; Purkinje Cells; Roscovitine; tau Proteins | 2004 |